Format

Send to

Choose Destination
Arch Bronconeumol. 2018 Oct;54(10):510-517. doi: 10.1016/j.arbres.2018.04.004. Epub 2018 Jun 23.

Screening for Latent Tuberculosis Infection in Patients who are Candidate for Biological Therapies in Spain? A Multidisciplinary Survey.

[Article in English, Spanish]

Author information

1
Servicio de Neumología, Hospital General Universitario La Paz-Carlos III- Cantoblanco, Madrid, España. Electronic address: saraiquiros@icloud.com.
2
Servicio de Neumología, Hospital Plató, Barcelona, España.
3
Servicio de Neumología, Hospital de Galdakao-Usansolo, Bizkaia, España.
4
Sección de Bioestadística - IdiPAZ, Hospital General Universitario La Paz, Madrid, España.
5
Servicio de Neumología, Hospital Clinic, Barcelona, España.
6
Servicio de Neumología, Hospital Comarcal Sant Jaume de Calella, Barcelona, España.
7
Servicio de Neumología, HUA Txagorritxu, Álava, España.
8
Servicio de Neumología, Hospital General de la Defensa, Zaragoza, España.
9
Servicio de Neumología, Hospital Universitario Marqués de Valdecilla, Santander, España.
10
Servicio de Neumología, Hospital Doctor Peset, Valencia, España.
11
Servicio de Neumología, Hospital Moisés Broggi, Barcelona, España.
12
Servicio de Neumología, Hospital Universitario de Albacete, Albacete, España.
13
Servicio de Neumología, Hospital Puerta de Hierro, Madrid, España.
14
Servicio de Neumología, Mutua de Terrassa, Barcelona, España.
15
Servicio de Neumología, HGU Gregorio Marañón, Madrid, España.
16
Servicio de Neumología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.

Abstract

INTRODUCTION:

Treatment with biological therapies increases the incidence of tuberculous disease. The introduction of systematic screening for latent tuberculosis infection in patients who are to receive these therapies has reduced this risk. In 2016, the consensus document on the prevention and treatment of tuberculosis in patients who are candidates for biological treatment was published in Spain. The main objective of this study was to evaluate adherence to these guidelines.

METHODS:

Multicenter, descriptive, observational study via an anonymous online survey sent to medical societies involved in biologics.

RESULTS:

We received 747 responses. Most respondents performed screening at the right time in the right patients (93.7%). Only 36.6% of respondents requested the appropriate diagnostic test, while 56.3% correctly recommended chemoprophylaxis. Up to 96% were familiar with the recommended chemoprophylaxis regimens, while only 63.9% initiated them at the right time. The specialist area that participated most and screened most patients for latent tuberculosis infection was rheumatology (54%). In most cases, pulmonologists were involved in an advisory capacity.

CONCLUSIONS:

This study shows poor overall adherence to recommendations, with only 56% of respondents reporting appropriate compliance. The incidence of tuberculous disease in patients who are to receive biological therapies could be reduced further by emphasizing the importance of the right diagnostic test and use of the diagnostic algorithm for latent tuberculosis infection.

KEYWORDS:

Biological therapies; Enfermedad tuberculosa; Factor de necrosis tumoral alfa; Infección tuberculosa latente; Latent tuberculosis infection; Terapias biológicas; Tuberculosis; Tumor necrosis factor-alpha

PMID:
29941293
DOI:
10.1016/j.arbres.2018.04.004
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center